Jason Barbour
Chief Executive Officer Echo Immune
Jason Barbour, PhD is the CEO of Echo Immunotherapeutics, where he leads the development of personalized mRNA cancer vaccines. His work focuses on integrating tumor genomics, immunology, and computational methods to enable practical neoantigen vaccine design in real-world clinical settings. He works closely with clinicians, researchers, and patients to translate sequencing data into individualized therapeutic strategies. His current focus is building scalable systems for adaptive, personalized cancer immunotherapy.
Seminars
Thursday 23rd July 2026
Founder Mode Oncology: Translating Personalised Neoantigen Vaccines from Bespoke to Scalable Systems
10:00 am
- From Maximal Diagnostics to Actionable Design: How multi-sample tumour sequencing (WES/RNA/Proteomics) and longitudinal data are translated into a constrained set of vaccine targets in real-world, often low–tumour mutational burden settings
- Epitope Selection as a Decision System: A practical framework for integrating neoantigen prediction algorithms, expression data, HLA binding, and tumour evolution using a structured “Epitope Board” that combines computational outputs with expert review
- Balancing Neoantigens and Tumour-Associated Antigens: Design strategies for combining patient-specific neoepitopes with validated shared antigens to improve target density and immune response in clinical settings where mutation burden is limited
